Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Yun, J ^a,h   Pannuti, A ^b   Espinoza, I ^b   Zhu, H ^b   Hicks, C ^b   Zhu, X ^b   Caskey, M ^b   Rizzo, P ^a,i   D'Souza, G ^c   Backus, K ^b   Denning, M F ^a   Coon, J ^d   Sun, M ^e   Bresnick, E H ^f   Osipo, C ^a   Wu, J ^f   Strack, P R ^g   Tonetti, D A ^b   Miele, L ^b  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

ⁱ UNIVERSITY OF FERRARA   (Italy)

Author keywords

breast cancer; endocrine therapy; Notch; PKC

Indexed keywords

GAMMA SECRETASE INHIBITOR; NOTCH1 RECEPTOR; NOTCH4 RECEPTOR; PROTEIN KINASE C ALPHA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; DNA REPLICATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STABLE EXPRESSION; TRANSIENT EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

EID: 84881405994     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.26     Document Type: Article

References (60)

1. Herold CI, Blackwell KL. Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. Clin Breast Cancer 2008; 8: 50-64. (Pubitemid 351346230)
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618. (Pubitemid 28536137)
3. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and anti-hormonal resistance in breast cancer. J Clin Oncol 2007; 25: 5815-5824.
4. Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract 2007; 61: 2051-2063. (Pubitemid 350077408)
5. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006; 66: 1517-1525. (Pubitemid 43259933)
6. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65: 8530-8537. (Pubitemid 41330622)
7. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007; 20: 685-693. (Pubitemid 46788875)
8. Yao K, Rizzo P, Rajan P, Albain K, Rychlik K, Shah S et al. Notch-1 and notch-4 receptors as prognostic markers in breast cancer. Int J Surg Pathol 2011; 19: 607-613.
9. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 2012; 109: 2742-2747.
10. Miele L. Notch signaling. Clin Cancer Res 2006; 12: 1074-1079. (Pubitemid 43342494)
11. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776. (Pubitemid 29291335)
12. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008; 68: 5226-5235.
13. Pink JJ, Bilimoria MM, Assikis J, Jordan VC. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 1996; 74: 1227-1236. (Pubitemid 26360111)
14. Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2000; 83: 782-791.
15. Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer 2003; 88: 1400-1402. (Pubitemid 36606422)
16. Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J. Protein kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat 2007; 104: 165-179. (Pubitemid 47084221)
17. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 2001; 7: 3156-3165. (Pubitemid 32963839)
18. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 2007; 60: 1216-1221. (Pubitemid 350084541)
19. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-1246. (Pubitemid 46640570)
20. Tien AC, Rajan A, Bellen HJ. A Notch updated. J Cell Biol 2009; 184: 621-629.
21. Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 2006; 27: 1538-1546. (Pubitemid 44288042)
22. Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res 2009; 7: 498-510.
23. Wu J, Iwata F, Grass JA, Osborne CS, Elnitski L, Fraser P et al. Molecular determinants of NOTCH4 transcription in vascular endothelium. Mol Cell Biol 2005; 25: 1458-1474. (Pubitemid 40204922)
24. Wu J, Bresnick EH. Glucocorticoid and growth factor synergism requirement for Notch4 chromatin domain activation. Mol Cell Biol 2007; 27: 2411-2422. (Pubitemid 46418491)
25. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997; 272: 18586-18594. (Pubitemid 27318198)
26. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene 1993; 8: 877-886. (Pubitemid 23087418)
27. Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW et al. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene 2010; 29: 201-213.
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
29. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010; 70: 709-718.
30. Molloy CA, May FE, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 2000; 275: 12565-12571. (Pubitemid 30241403)
31. Cesarone G, Garofalo C, Abrams MT, Igoucheva O, Alexeev V, Yoon K et al. RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells. J Biol Chem 2006; 98: 440-450.
32. Knowlden JM, Gee JM, Barrow D, Robertson JF, Ellis IO, Nicholson RI et al. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Res 2011; 13: R93.
33. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R et al. Tamoxifen resistance in MCF-7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006; 118: 290-301. (Pubitemid 41779067)
34. Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF-7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 2012; 12: 458.
35. Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR et al. Loss of Rho GDIalpha and resistance to tamoxifen via effects on estrogen receptor alpha. J Natl Cancer Inst 2011; 103: 538-552.
36. Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010; 29: 2983-2995.
37. Bergamaschi A, Christensen BL, Katzenellenbogen BS. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3zeta, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res 2011; 13: R70.
38. Lee CW, Raskett CM, Prudovsky I, Altieri DC. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 2008; 68: 5273-5281.
39. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
40. Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and pro-survival functions in tumor cells. Cancer Res 2007; 67: 9214-9220. (Pubitemid 47535908)
41. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 2009; 4: e5821.
42. Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V et al. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 2009; 85: 421-431.
43. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 2008; 105: 18490-18495.
44. Jhappan C, Gallahan D, Stahle C, Chu E, Smith GH, Merlino G et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev 1992; 6: 345-355.
45. Smith GH, Gallahan D, Diella F, Jhappan C, Merlino G, Callahan R. Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell Growth Differ 1995; 6: 563-577.
46. Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E et al. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 1996; 56: 1775-1785. (Pubitemid 26118213)
47. Gallahan D, Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene 1997; 14: 1883-1890. (Pubitemid 27217801)
48. Callahan R, Raafat A. Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6: 23-36. (Pubitemid 33640644)
49. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004; 9: 145-163. (Pubitemid 39177500)
50. Imatani A, Callahan R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000; 19: 223-231. (Pubitemid 30077218)
51. Raafat A, Lawson S, Bargo S, Klauzinska M, Strizzi L, Goldhar AS et al. Rbpj conditional knockout reveals distinct functions of Notch4/Int3 in mammary gland development and tumorigenesis. Oncogene 2009; 28: 219-230.
52. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-157. (Pubitemid 121007534)
53. Chen DB, Davis JS. Epidermal growth factor induces c-fos and c-jun mRNA via Raf-1/MEK1/ERK-dependent and-independent pathways in bovine luteal cells. Mol Cell Endocrinol 2003; 200: 141-154. (Pubitemid 36331922)
54. Rosenberger SF, Finch JS, Gupta A, Bowden GT. Extracellular signal-regulated kinase 1/2-mediated phosphorylation of JunD and FosB is required for okadaic acid-induced activator protein 1 activation. J Biol Chem 1999; 274: 1124-1130. (Pubitemid 29058089)
55. Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 2007; 14: 293-303. (Pubitemid 47242630)
56. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-193. (Pubitemid 33741893)
57. Albain K, Czerlanis C, Zlobin A, Covington KR, Rajan P, Godellas C et al. Modulation of cancer stem cell biomarkers by the Notch inhibitor MK0752 added to endocrine therapy for early stage ER + breast cancer. Cancer Res 2011; 71: 97s.
58. Means-Powell JA, Minton SE, Mayer IA, Abramson VG, Ismail-Khan R, Arteaga CL et al. A phase Ib dose escalation trial of RO4929097 (a g-secretase inhibitor) in combination with Exemestane in patients with ER + metastatic breast cancer. Cancer Res 2012; 72: 280s.
59. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112. (Pubitemid 20213250)
60. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003; 95: 1586-1597. (Pubitemid 37455926)